• NervGen Pharma entered an at-the-market sales agreement with Leerink Partners to offer up to USD 50 million of common shares.
• Sales may be made from time to time on Nasdaq at prevailing market prices, subject to company-set limits in each placement notice.
• Leerink will receive a 3% cash commission on gross proceeds from placement share sales.
• Settlement is expected on the next trading day unless otherwise specified, with shares delivered electronically through DTC’s DWAC system.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. NervGen Pharma Corp. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001104659-26-080432), on July 02, 2026, and is solely responsible for the information contained therein.